William F. Martin

William F. Martin

Auto-generated profile, based on publicly available information

William F. Martin

Alkermes, Inc., Waltham, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2005 in Nutrition & Metabolism
Verified
Journal Article
Open access
WMWilliam F Martin
William F Martin
LALawrence E. Armstrong
Lawrence E. Armstrong
NRNancy R. Rodriguez
Nancy R. Rodriguez
Recent trends in weight loss diets have led to a substantial increase in protein intake by individuals. As a result, the safety of habitually consuming dietary protein in excess of recommended intakes has been questioned. In particular, there is concern that high protein intake may promote renal damage by chronically increasing glomerular pressure and hyperfiltration. There is, however, a serious question as to whether there is significant evidence to support this relationship in healthy individuals. In fact, some studies suggest that hyperfiltration, the purported mechanism for renal damage, is a normal adaptative mechanism that occurs in response to several physiological conditions. This paper reviews the available evidence that increased dietary protein intake is a health concern in terms of the potential to initiate or promote renal disease. While protein restriction may be appropriate for treatment of existing kidney disease, we find no significant evidence for a detrimental effect of high protein intakes on kidney function in healthy persons after centuries of a high protein Western diet.

1 February 2006 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
MPMatthew A Pikosky
Matthew A Pikosky
PGPatricia C. Gaine
Patricia C. Gaine
WMWilliam F. Martin
William F. Martin
KGKimberly C. Grabarz
Kimberly C. Grabarz
AFArny A Ferrando
Arny A Ferrando
NRNancy R. Rodriguez
Nancy R. Rodriguez
The effect of a 4-wk aerobic exercise training program (30–45 min, 3–5 d/wk, ≥65% maximal heart rate) on mixed skeletal muscle protein fractional synthetic rate (FSR), fractional breakdown rate (FBR), and net protein balance (FSR − FBR) (NET) was examined in 8 healthy, previously unfit men and women [21.0 ± 0.4 y, 163.7 ± 4.4 cm, 75.6 ± 5.7 kg, 33.5 ± 4.1% body fat, VO2peak 38.6 ± 2.3 mL/(kg·min)] fed eucaloric diets providing 0.85 g protein/(kg·d) for the 6-wk study. Measurements were made at baseline after 2 wk of diet intervention only, and after 4 wk of aerobic exercise training and diet intervention. Primed continuous infusions of ring-[2H5]-phenylalanine (2 μmol/kg; 0.05 μmol/(kg·min) and [15N]-phenylalanine (2 μmol/kg; 0.05 μmol/(kg·min) were used to assess skeletal muscle protein turnover at rest via the precursor-product method. Endurance training improved cardiovascular fitness, with a significant increase in VO2peak (P < 0.01) and a significant decrease in running time on a standard course (P < 0.01). There were no significant changes in body mass or composition. There was a significant increase in FSR (0.077 ± 0.007 vs. 0.089 ± 0.006%/h, P < 0.05) and decrease in NET (FSR − FBR) (−0.023 ± 0.004 vs. −0.072 ± 0.012%/h, P < 0.05); FBR tended to increase (0.105 ± 0.014 vs. 0.143 ± 0.018%/h; P = 0.06) after training. Findings show that aerobic training for 4 wk increases skeletal muscle protein turnover in previously unfit subjects.

29 October 2018 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
MFMaurizio Fava
Maurizio Fava
MTMichael E. Thase
Michael E. Thase
MTMadhukar Trivedi
Madhukar Trivedi
EEElliot Ehrich
Elliot Ehrich
WMWilliam F. Martin
William F. Martin
SPSanjeev Pathak
Sanjeev Pathak
The endogenous opioid system is thought to play an important role in the regulation of mood. Buprenorphine/samidorphan (BUP/SAM) combination is an investigational opioid system modulator for adjunctive treatment of major depressive disorder (MDD). To confirm results from early studies, we report the efficacy and safety of BUP/SAM as adjunctive treatment in patients with MDD and an inadequate response to antidepressant therapy (ADT) in FORWARD-4 and FORWARD-5: two phase 3, randomized, double-blind, placebo-controlled studies that utilized the same sequential parallel-comparison design. Efficacy was measured using the Montgomery–Åsberg Depression Rating Scale (MADRS). FORWARD-5 achieved the primary endpoint and demonstrated that adjunctive BUP/SAM 2 mg/2 mg was superior to placebo (average difference change from baseline to week 3 through end of treatment [EOT] in MADRS-6 and −10 versus placebo: −1.5, P = 0.018; −1.9, P = 0.026, respectively). FORWARD-4 did not achieve the primary endpoint (change from baseline in MADRS-10 at week 5 versus placebo: –1.8, P = 0.109), although separate analyses showed significant treatment differences at other timepoints using traditional, regulatory-accepted endpoints such as reduction in MADRS-10 at EOT. The pooled analysis of the two studies demonstrated consistently greater reduction in MADRS-10 scores from baseline for BUP/SAM 2 mg/2 mg versus placebo at multiple timepoints including EOT and average change from baseline to week 3 through EOT (–1.8, P = 0.010; –1.8, P = 0.004, respectively). The overall effect size (Hedges’ g) in the pooled analyses for MADRS-10 change from baseline to EOT was 0.22. Overall, BUP/SAM was generally well tolerated, with most adverse events (AEs) being mild or moderate in severity. The most common AEs, occurring in ≥5% of patients in the BUP/SAM 2 mg/2 mg treatment group, which was more frequently than the placebo group, included nausea, constipation, dizziness, vomiting, somnolence, fatigue, and sedation. There was minimal evidence of abuse, and no evidence of dependence or opioid withdrawal by AEs or objective measures. This report describes adjunctive BUP/SAM 2 mg/2 mg combination, a therapy with a novel opioidergic mechanism of action, as a potential new treatment option for patients with MDD who have an inadequate response to currently available ADT.

1 May 2018 in Schizophrenia Research
Verified
Journal Article
Open access
BSBernard L. Silverman
Bernard L. Silverman
WMWilliam Martin
William Martin
AMAsli Memisoglu
Asli Memisoglu
LDLauren DiPetrillo
Lauren DiPetrillo
CCChristoph U. Correll
Christoph U. Correll
JKJohn M. Kane
John M. Kane
Antipsychotic medications are associated with weight gain and adverse metabolic effects that complicate the treatment and management of schizophrenia. Olanzapine (OLZ) in particular is associated with significant weight gain and adverse metabolic effects. The present Phase 1, proof of concept, multicenter, randomized, double-blind, placebo-controlled study investigated the safety and effect on weight of a combination of OLZ (10mg) and the opioid modulator samidorphan (SAM; 5mg) in comparison to OLZ alone in healthy, male normal weight volunteers. Altogether, 106 male subjects with stable body weight and BMI 18-25kg/m2 were randomized to OLZ alone, OLZ+SAM, SAM alone, or placebo in a 2:2:1:1 ratio. The primary efficacy endpoint, mean (SD) body weight change from baseline to last assessment in the 3-week treatment period, was significantly less for OLZ+SAM vs. OLZ alone subjects [+2.2 (1.4) kg vs. +3.1 (1.9) kg; respectively; p=0.02]. In contrast, there was no significant difference in weight from baseline for either SAM or placebo [+0.1 (1.0) kg and +0.8 (1.4) kg, respectively]; p=0.09. Overall, OLZ+SAM compared to OLZ alone had similar safety and tolerability. In addition, less nausea was observed in subjects given OLZ+SAM compared to SAM alone. Thus, OLZ+SAM may offer effective treatment of schizophrenia with less weight gain and metabolic risk. Additional research exploring additional doses over longer durations in psychiatric populations is warranted.

1 April 2006 in Metabolism
Verified
Journal Article
Closed access
PGPatricia C. Gaine
Patricia C. Gaine
MPMatthew A. Pikosky
Matthew A. Pikosky
WMWilliam F. Martin
William F. Martin
DBDouglas R. Bolster
Douglas R. Bolster
CMCarl M. Maresh
Carl M. Maresh
NRNancy R. Rodriguez
Nancy R. Rodriguez

1 April 2019 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
JZJohn M Zajecka
John M Zajecka
ASArielle D Stanford
Arielle D Stanford
AMASLI MEMISOGLU
ASLI MEMISOGLU
WMWilliam F Martin
William F Martin
SPSanjeev Pathak
Sanjeev Pathak
Background: The endogenous opioid system is a fundamental regulator of mood in humans. Previously reported clinical trials have demonstrated the efficacy of the investigational agent buprenorphine/samidorphan (BUP/SAM) combination, an opioid-system modulator, for the adjunctive treatment of major depressive disorder. We present here a third phase III study of different design. Methods: Adult patients with major depressive disorder and inadequate response to antidepressant therapy were enrolled in this double-blind, placebo-controlled, placebo run-in study to evaluate the efficacy, safety, and tolerability of adjunctive BUP/SAM 2 mg/2 mg. Patients with baseline Hamilton Depression Rating Scale score ≥20 received double-blind placebo in addition to background antidepressant therapy for 4 weeks. Nonresponders were randomized to receive adjunctive BUP/SAM 2 mg/2 mg or placebo for 6 weeks. The primary end point was change in Montgomery–Åsberg Depression Rating Scale (MADRS)-10 total score from randomization at baseline to the end of the 6-week treatment period. Results: Least-squares mean change in MADRS-10 score at end of treatment was -4.8 (SE 0.67) in the BUP/SAM 2 mg/2 mg group and -4.6 (SE 0.66) in the placebo group (mean difference -0.3 [SE 0.95], P=0.782). There were no differences in MADRS-based response or remission rates. Overall, 42.9% of the BUP/SAM 2 mg/2 mg group and 34.5% of the placebo group experienced at least one treatment-emergent adverse event during the 6-week treatment period, most of which were mild or moderate in severity. There were no clinically important changes in laboratory parameters, weight, or vital signs and no evidence of abuse potential during treatment or opiate-withdrawal symptoms post treatment. Conclusion: Efficacy results in FORWARD-3 measured by change in MADRS-10 score did not meet the primary end point, but postbaseline improvement in MADRS-10 in the BUP/SAM 2 mg/2 mg group was consistent with that seen in previously reported trials. BUP/SAM 2 mg/2 mg was well tolerated.